Characterization of response-adapted surgery following neoadjuvant systemic therapy in oral cavity cancer
- 30 June 2026
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 180, 108060
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
- National Cancer Institute (K08CA283306)
This publication has 16 references indexed in Scilit:
- Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCCOtolaryngology–Head and Neck Surgery, 2025
- Defining response-adapted surgery after neoadjuvant therapy in oral cavity cancerOral Oncology, 2025
- Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective studyCancer Immunology, Immunotherapy, 2025
- A preliminary analysis of patient reported outcomes following posterolateral mandible reconstruction: The role of flap typeJournal of Surgical Oncology, 2023
- Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trialEuropean Journal of Cancer, 2021
- Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysisOral Oncology, 2020
- Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancersOral Oncology, 2014
- Long-term Health-Related Quality of Life in Survivors of Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2012
- Long-term Quality of Life for Surgical and Nonsurgical Treatment of Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2005
- Are head and neck specific quality of life measures necessary?Head & Neck, 1997